Company Description
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.
The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.
It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California.
The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
| Country | United States |
| Founded | 2007 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 800 |
| CEO | Daniel Virnich |
Contact Details
Address: 18000 Studebaker Road, Suite 800 Cerritos, California 90703 United States | |
| Phone | 562 735 3226 |
| Website | theoncologyinstitute.com |
Stock Details
| Ticker Symbol | TOI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001799191 |
| CUSIP Number | 68236X100 |
| ISIN Number | US68236X1000 |
| Employer ID | 84-3562323 |
| SIC Code | 8011 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Virnich FACHE, M.B.A., M.D. | Chief Executive Officer and Executive Director |
| Richard Alan Barasch | Chairman of the Board |
| Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H. | Chief Medical Officer |
| Rob Carter | Chief Financial Officer |
| Jeremy N. Castle M.B.A. | Chief Operations Officer |
| Austin Lee | Vice President of Accounting and Controller |
| Mark Hueppelsheuser Esq. | General Counsel |
| Jordan McInerney | Chief Development Officer |
| Stephen Cella | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2025 | ARS | Filing |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 14, 2025 | PRE 14A | Other preliminary proxy statements |